PA Capital’s MacroGenics MGNX Stock Holding History

PA Capital’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,574	Closed	-$134K	–	127
2018 Q4	$134K	Buy	+10,574	New	+$177K	0.14%	101

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PA Capital's MGNX Position: Q1 2019 in Review

PA Capital sold out of MacroGenics (MGNX) in Q1 2019, closing a stake of 10,574 shares — an estimated $134K sold.

PA Capital first reported a position in MGNX in Q4 2018 and held it in 1 quarter. The position peaked at $134K in Q4 2018. 157 funds tracked by Wall St. Rank hold MGNX as of Q1 2019.

PA Capital reported no remaining MacroGenics position as of Q1 2019 after selling out during the quarter.
PA Capital sold 10,574 MacroGenics shares in Q1 2019, an estimated $134K.
PA Capital first reported a position in MacroGenics in Q4 2018 and held it in 1 quarter.
PA Capital's MacroGenics position peaked at $134K in Q4 2018.
157 funds tracked by Wall St. Rank held MacroGenics as of Q1 2019.

Based on PA Capital's 13F filing for Q1 2019, filed 10 May 2019.